Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$12.30 USD
+0.09 (0.74%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Arcturus Therapeutics Holdings Inc. has a market cap of $331.14M, which represents its share price of $12.21 multiplied by its outstanding shares number of 27.12M. As a small-cap company, ARCT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ARCT 12.30 +0.09(0.74%)
Will ARCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Other News for ARCT
ARCT Crosses Above Key Moving Average Level
Arcturus Therapeutics (ARCT) Maintains Sector Outperform; Price Target Raised | ARCT Stock News
Arcturus Therapeutics price target raised by $3 at Scotiabank, here's why
Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts